Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01420588
Other study ID # DGLES
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 1, 2011
Est. completion date January 30, 2020

Study information

Verified date May 2020
Source Anhui Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The investigators study the feasibility of a novel method in oncology based on breath analysis with a nanosensors array for identifying gastric diseases. Alveolar exhaled breath samples collected from volunteers referred for upper endoscopy or surgery are analyzed using a custom-designed array of chemical nanosensors based on organically functionalized gold nanoparticles and carbon nanotubes. Predictive models are built employing discriminant factor analysis (DFA) pattern recognition method. Classification accuracy, sensitivity and specificity are determined using leave-one-out cross-validation or an independent blind test set. The chemical composition of the breath samples is studied using gas chromatography coupled with mass spectrometry (GC-MS).

A pilot study is conducted first (enlistment of 160 subjects at the Department of Oncology, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.)

The pilot study is followed by a large-scale clinical trial to confirm the preliminary results of the Chinese pilot study (enlistment of 800 subjects at the Digestive Diseases Centre GASTRO, Riga East University Hospital, 6 Linezera iela, LV1006 Riga, Latvia). 25% of the samples are used as independent blind test set. The samples are blinded by the medical team and are not disclosed until prediction of blind sample identity is complete.

To further prove the diagnosis of GC from exhaled breath and seek the interrelationship among Breathomics, metabolomics and transcriptomics, saliva samples from about 200 patients are collected from volunteers referred for upper endoscopy or surgery are analyzed using Ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS). Simultaneously, RNA sequencing are preformed on gastric cancer tissue samples and paracancerous tissue samples collected from same group of volunteers. The data of salivary metabonomics and transcriptomics were integrated and analyzed on the on Kyoto Encyclopedia of Genes and Genomes to confirm the diagnostic validity of salivary metabonomics.


Description:

Number of patients that will have a definitive diagnosis and Alveolar exhaled breath samples collected from individuals with Tedlar® bags (Keika Ventures, LLC) after endoscopy.. Two breath samples were collected from each person tested.

Two-bed sorption tubes filled with the following sorbents were used as traps for sample collection with simultaneous preconcentration: 100mg matrix Tenax TA and 50mg matrix Tenax TA (35-60 mesh; purchased from Supelo, Bellefonte, PA). Sorbents were separated by glass wool. The samples were collected at a total flow through sorption trap of 200ml/min.

One sample was used for analysis with the nanosensors array, and the other sample was used for Gas Chromatography coupled with Mass Spectrometry (GC-MS) analysis.

Cancer tissue and paracancerous tissue samples were collected in the process of surgical resection. After collection in the operating room, the samples were immediately placed in - 5 ℃ dry ice and transferred to the laboratory. Then, the samples were frozen in liquid nitrogen for 30 minutes, and then placed in - 80℃ freezer for cold storage. After that, the samples were divided into several batches and transported in dry ice for subsequent transcriptome analysis. All the saliva samples were collected using 2ml cryopreservation tube during early morning before surgery or endoscopic resection. The patient had been told not to eat after 22 o'clock the night, and not to drink water, smoke, brush teeth or exercise violently one hour before the collection. The saliva samples were sealed in the -80 C refrigerator after collection and then transported in a foam box equipped with dry ice, followed by UHPLC-MS analysis.


Recruitment information / eligibility

Status Completed
Enrollment 1000
Est. completion date January 30, 2020
Est. primary completion date May 1, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- 18-75 years

- Gastric cancer, gastric ulcer, gastritis,

- No previous adjuvant treatment (surgery, radiotherapy, chemotherapy)

- Gastric lesions are diagnosed by gastroendoscopy and histopathologic.

- ECOG < 2

Exclusion Criteria:

- Other palliative chemotherapy and radiotherapy for this cancer

- Other cancer

- diabetes , Fatty liver

- Autoimmune disease

- Ventilation and transaired function obstacle

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Department of Oncology, The First Affiliated Hospital of Anhui Medical University Hefei Anhui
Latvia Faculty of Medicine, University of Latvia Riga

Sponsors (3)

Lead Sponsor Collaborator
Anhui Medical University Technion, Israel Institute of Technology, University of Latvia

Countries where clinical trial is conducted

China,  Latvia, 

References & Publications (3)

Amal H, Leja M, Funka K, Skapars R, Sivins A, Ancans G, Liepniece-Karele I, Kikuste I, Lasina I, Haick H. Detection of precancerous gastric lesions and gastric cancer through exhaled breath. Gut. 2016 Mar;65(3):400-7. doi: 10.1136/gutjnl-2014-308536. Epub — View Citation

Peng G, Tisch U, Adams O, Hakim M, Shehada N, Broza YY, Billan S, Abdah-Bortnyak R, Kuten A, Haick H. Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nat Nanotechnol. 2009 Oct;4(10):669-73. doi: 10.1038/nnano.2009.235. Epub 2009 Aug 30. — View Citation

Xu ZQ, Broza YY, Ionsecu R, Tisch U, Ding L, Liu H, Song Q, Pan YY, Xiong FX, Gu KS, Sun GP, Chen ZD, Leja M, Haick H. A nanomaterial-based breath test for distinguishing gastric cancer from benign gastric conditions. Br J Cancer. 2013 Mar 5;108(4):941-50 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Proof seeking from metabolomics and transcriptomics Salivary samples collected from 200 subjects referred for upper endoscopy or surgery are analyzed using Ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS). Predictive models are built employing discriminant factor analysis (DFA). Classification accuracy, sensitivity and specificity were determined using leave-one-out cross-validation.
Data from breathomics, salivary metabonomics and transcriptomics are integrated to seek the proof of breath diagnosis at different levels.
2 weeks after the data analyses
Primary Discrimination between Malignant and Benign Gastric Lesions with Na-nose Proof-of-concept:
Alveolar exhaled breath samples collected from 160 subjects referred for upper endoscopy at The First Affiliated Hospital of Anhui Medical University are analyzed using a custom-designed array of chemical nanosensors. Predictive models are built employing discriminant factor analysis (DFA). Classification accuracy, sensitivity and specificity were determined using leave-one-out cross-validation. The chemical composition is studied using gas chromatography coupled with mass spectrometry (GC-MS).
Confirmation of proof-of-concept:
Alveolar exhaled breath samples collected from 800 subjects referred for upper endoscopy at Riga East University Hospital are analyzed as was used in the pilot study. Predictive models are built as in the pilot study,using a training set of only 75% of the samples. Classification accuracy, sensitivity and specificity are determined using an independent blind test set (25% of the samples)
2 weeks after the collection of breath
Secondary Geographical comparison of VOCs between China and Latvia Specifically, to compare the VOCs that distinguish between malignant and benign gastric lesions in the Chinese and Latvian cohorts. The cohorts from China and Latvia are matched in terms of sample size, gender ratio, average age, and smoking habits. 2 weeks after the data analyses
See also
  Status Clinical Trial Phase
Recruiting NCT05069233 - Magnetically Controlled Capsule Endoscopy in Visualization of the UGI and Small Intestine
Completed NCT00745459 - Phase III General Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy Phase 3
Active, not recruiting NCT05602935 - Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study Phase 2
Completed NCT03549494 - Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction Phase 2
Completed NCT00977678 - Drop in Gastroscopy - Experience After 9 Months N/A
Terminated NCT00577772 - Transit Time and Bacterial Overgrowth Using SmartPill Capsule N/A
Completed NCT03514966 - Repetitive Position Change Improves Gastric Cleanliness for MCE N/A
Recruiting NCT02846155 - Gastric Preparation of Magnetic-controlled Capsule Endoscopy Phase 2
Not yet recruiting NCT03889626 - The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer Phase 3
Active, not recruiting NCT02476097 - PROGRESSive Withdrawal Esomeprazole and Acid-related Symptoms Phase 4
Completed NCT01576380 - A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients Phase 2
Completed NCT00682877 - A Comparison of SmartPill Capsule With Scintigraphy for Determining Gastric Residence Time - Over 65 Years Old N/A
Completed NCT00128284 - A Comparison of SmartPill Capsule With Scintigraphy for Determining Gastric Residence Time N/A